The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Beigene; Bristol-Myers Squibb; Incyte; Janssen; Kite, a Gilead Company; Regeneron; Roche
Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.
 
Jose Caetano Villasboas
Consulting or Advisory Role - Curio Science (Inst); Kite/Gilead (Inst); Regeneron (Inst); TG Therapeutics (Inst)
Research Funding - Aptose Biosciences (Inst); Enterome (Inst); Epizyme (Inst); Genentech/Roche (Inst); Regeneron (Inst)
 
Laura Magnano Mayer
No Relationships to Disclose
 
Benoît Tessoulin
Honoraria - Abbvie; Kite/Gilead
Travel, Accommodations, Expenses - Abbvie; Kite/Gilead
 
Seok-Goo Cho
Stock and Other Ownership Interests - LucasBio; ViGen Cell
 
Michal Taszner
Consulting or Advisory Role - Roche; Takeda
 
Silvana Novelli
Consulting or Advisory Role - Mundipharma
Research Funding - Novartis
 
Stefano Luminari
No Relationships to Disclose
 
Michele Merli
Travel, Accommodations, Expenses - Janssen
 
Ana Jiménez Ubieto
No Relationships to Disclose
 
Michelle Poon
No Relationships to Disclose
 
David Tucker
Consulting or Advisory Role - Abbvie; BeiGene; Gilead Sciences; Immunovant; Regeneron
Travel, Accommodations, Expenses - BeiGene
 
Jan Andrzej Walewski
Honoraria - Abbvie; Gilead Sciences; Novartis; Roche
Consulting or Advisory Role - Abbvie; Gilead Sciences; Novartis; Roche; Takeda/Millennium
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Epizyme; Gilead Sciences; GlaxoSmithKline; Incyte; Janssen-Cilag; Karyopharm Therapeutics; Loxo/Lilly; MorphoSys; MSD Oncology; NanoVector; Novartis (Inst); Regeneron; Seagen; Takeda; TG Therapeutics; Vanda Pharmaceuticals (Inst)
 
Cristina Ivanescu
Employment - IQVIA
Consulting or Advisory Role - Various pharma companies, such as BMS, Regeneron, Astellas, etc. (Inst)
 
Aafia Chaudhry
Employment - Regeneron
 
Hesham Mohamed
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Odronextamab related patents
 
Srikanth R. Ambati
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
James Harnett
Employment - Regeneron
Stock and Other Ownership Interests - Pfizer; Regeneron
 
Siddhesh Kamat
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; IMBdx; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Dizal Pharma (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)